8月11日，直觉外科盘中上涨3.03%，报390.24美元/股，成交额6.81亿美元。消息面上，公司此前公布二季度财报，调整后每股收益2.80美元，远超市场预期的2.50美元，营收28.92亿美元同比增长18%，全球达芬奇手术量同比增长15%。尽管公司维持全年手术量增长13.5%-15.5%的展望未做上调，股价在财报后一度重挫逾11%，年初至今累计下跌逾33%。
近期多家机构重申积极立场，瑞银于7月底将公司评级上调至"买入"，目标价500美元；BMO此前指出公司股价较三年历史市盈率折价约31%，存在历史性配置机会。当日医疗设备板块整体走强，德康医疗涨3.62%、波士顿科学涨2.85%、美敦力涨2.0%，板块联动推动公司延续超跌反弹态势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.